

COVID-19 publications au niveau européen – Actualisation au 31/03/2020

Commission Européenne:

- New [COVID-19 Clinical Management Support System](#) to support clinicians in hospitals that are facing the coronavirus emergency. The initiative aims to create rapid connections across Europe among the hospitals indicated by the Member States as reference centres for COVID-19. Clinicians can rely on a dedicated helpdesk managed by DG SANTE to set up web conferences and exchange with their peers in Europe on possible treatments, and on how to handle severe and complex cases.
- [Health Security Committee \(HSC\) sets up ad-hoc Working Group on the clinical case management](#): The WG is open to Member States and will discuss enrolment of clinical trials participants, and exchange of information and best clinical practices across the EU and to help coordinate relevant activities.
- [European standards for medical supplies made freely available to facilitate increase of production](#): Upon request by the Commission, the European Committee for Standardization (CEN) and the European Committee for Electrotechnical Standardization (CENELEC) share European standards for certain medical devices and personal protective equipment to improve production capacity.
- [Commission steps up research funding and selects 17 projects in vaccine development, treatment and diagnostics](#): Following the publication of a €10 million call in January, the Commission has secured an additional €37.5 million for urgently needed research on COVID-19 vaccine development, treatment and diagnostics.
- Commission discusses with telecom operators' the need to [collect and share anonymised mobile metadata \(ex. user location\) to model and predict the propagation of COVID-19](#), as well as network resilience against cyberattacks. This coordinated action comes as a response to the wish of Member States to geolocate individuals or to send public health messages in a specific area via mobile phone. The impact that such actions could have on the fundamental rights to privacy and data protection, led the [EDPB to issue a statement on the processing of personal data in the context of the COVID-19 outbreak](#), including a section about access and disclosure of health data when an employee contracted COVID-19. Equally, the [EDPS wrote to the Commission advising on how to handle the monitoring of the spread of COVID-19](#), while recognising flexibility to restrict those fundamental rights.
- [Guidelines concerning the exercise of the free movement of workers during COVID-19 outbreak](#): The European Commission provides guidance for the cross-border flows of frontier workers and posted workers in essential professions including health professions, to allow for continued free movement in critical sectors, notwithstanding safety measures such as health screenings.

Parlement Européen:

- [Parliament approves crucial EU support measures](#): the European Parliament has approved support in form of the [Corona Response Investment Initiative](#), an [extension of the EU Solidarity Fund](#), a [temporarily suspending EU rules on airport slots](#), and [joint procurement agreements](#) for medical equipment.

Conseil Européen:

- [European Council asks Commission to make proposals](#) for a more ambitious and wide-ranging crisis management system within the EU.

Centre Européen de prévention et de contrôle des Maladie

- [Infection prevention, control and preparedness for COVID-19 in healthcare settings](#): ECDC published a third update of a guidance that focuses on measures to be applied in settings with increasing community transmission, a growing demand for care of COVID-19 patients and

ensuing staff issues in the event of shortages of personal protective equipment for healthcare facilities.

Agence Européenne des Médicaments:

- [EMA has implemented a new system to issue electronic certificates for medicines](#): the Agency will no longer provide printed certificates but only electronically signed and authenticated certificates to maintain EMA's ability to provide these documents during the COVID-19 pandemic.
- [Guidance on the management of clinical trials during the COVID-19 \(coronavirus\) pandemic](#) has been updated to cover safety reporting, the distribution of in-vitro diagnostics, medical devices and auditing. The updated guidance also incorporates changes in other sections, in particular on communicating with authorities, informed consent and the distribution of investigational medicines.
- [EMA advises](#) patients and healthcare professionals that angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs, or sartan medicines) can continue to be used to treat high blood pressure, heart failure or kidney disease during the COVID-19 pandemic. EMA will keep its information on new [COVID-19-related treatment recommendations](#) up to date.
- EMA and the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) encourage all researchers to register their pharmacoepidemiological studies related to the COVID-19 pandemic in the [EU PAS Register](#). They should also upload and make their study protocols public, with a description of the data collected or planned to be collected.

▪ **OMS/OMS Europe**

▪ **Conseils pour le Covi-19 et les groupes à risque**

- [Preparedness, prevention and control of COVID-19 in prisons and other places of detention](#):

The technical guidance addresses the management of suspect cases, probable cases, and confirmed cases of infections in the prison setting, as well as specific considerations relating to human rights, prevention and discharge

- [Mental health and COVID-19](#): briefing notes and infographics on coping with stress, i.a. for persons dealing with children

- [Information poster for children](#): produced by [www.covid19parenting.com](#) in English

- [Q&A on COVID-19, pregnancy, childbirth and breastfeeding](#): frequently asked questions as well as technical guidance for before, during and after birth

▪ **Recueil des orientations techniques de l'OMS Genève**

[Quick Links](#): overview of all WHO resources and news

[Technical Guidance: Infection Prevention and Control](#): WHO technical guidance documents including:

[Advice on the use of masks in the community, during home care and in healthcare settings in the context of the novel coronavirus \(COVID-19\) outbreak](#)

[Situation Reports](#) and [Dashboard](#): updated data on transmission, infections and mortality

[Myth busters](#): information texts and posters on transmission and treatment myths for general public

[Compilation of academic papers circulated by WHO Global Patient Safety Network](#): This is a link to a regularly updated compilation of academic studies by various authors shared by Donald M. Berwick, MD, MPP, President Emeritus and Senior Fellow, Institute for Healthcare Improvement. It covers i.a. epidemiology, radiology, immunology, anaesthesiology, and

paediatrics, as well as horizontal topics such as ethical questions and use of personal protective equipment.

[WHO survey how to best upscale training](#): This anonymous survey for individuals seeks to assess the feasibility of (online) training for health professionals in terms of their access to tools, time etc.

[SOLIDARITY: WHO announced a large multi-country clinical trial](#): the trial, which includes 45 countries and counting, will test four drugs and drug combinations' (remdesivir, lopinavir and ritonavir in combination; lopinavir/ritonavir plus interferon-beta; and chloroquine and hydroxychloroquine) effectiveness against the COVID-19. On Friday 27 March [the first patient](#) was enrolled in the trial.

Rapports Nationaux:

- [Compulsory licensing as a potential response to COVID-19](#): several countries are taking pre-emptive measures to facilitate access to vaccines, drugs, diagnostics, devices, supplies, and other technologies useful in tackling the COVID-19. [Chile](#) and [Israel](#) have already restricted patents relating to COVID-19 and other countries like [Ecuador](#), [Canada](#) and [Germany](#) are considering appropriate legislative changes. A compulsory licence suspends the monopoly effect of a patent and allows others than the patent holder to produce and supply the product.

Rapports d'autres sources:

- [A summary of the current knowledge and available resources](#): This compilation is prepared by the Section of Infectious Diseases of UEMS and includes information i.a. on transmission and possible treatments.
- [Mapping of Sanitary decisions](#): the Fondation Robert Schuman has mapped containment measures across Europe and prepared an [analysis](#) of European and national decisions.
- International Society for Quality in Health Care (ISQua) [PATIENT SAFETY RECOMMENDATIONS FOR COVID19 EPIDEMIC OUTBREAK](#):
- [EJD statement](#) regarding the Covid-19 pandemic.
- Sara Albolino, Ph.D., Chair WHO Collaborating Centre, Director Centre for Patient Safety Tuscany, Italy and Giulia Dagliana, PSM, MSc., Coordinator WHO Collaborating Centre Human Factor and Communication for Safe and Quality Care Tuscany, Italy [on COVID-19 lessons learned](#).
- [The European Hospital and Healthcare Federation \(HOPE\)](#) reiterates its support to the hospital and healthcare services professionals and express their admiration for their commitment and courage.